Sard Verbinnen & Co. represents Cue Health as the San Diego health technology company and maker of home test kits for COVID-19 readies an initial public offering.
The company's goal is to enable people to manage their health through real-time, actionable and connected health data.
Cue envisions a suite of testing kits to provide consumers lab-quality results in 20 minutes without the need to visit a medical facility.
It is working on test kits for influenza, respiratory syncytial virus, fertility, pregnancy and inflammation. Cue plans to file for FDA approval for those kits during the second half of next year.
The company signed a $480M agreement with the Pentagon and Dept of Health and Human Services in Oct. 2020 for 6M of its test kits.
The National Basketball Assn. counted on the Cue COVID-19 test during its 2020 “bubble season.”
Cue posted $201M in first-half revenues and earned $32.8M.
It plans to list its stock on the NASDAQ.